Literature DB >> 3678274

The value of determination of homovanillic and vanillylmandelic acids in plasma for the diagnosis and follow-up of neuroblastoma in children.

M Gahr1, D H Hunneman.   

Abstract

The plasma levels of homovanillic and vanillylmandelic acids were determined in 84 children with neuroblastoma prior to treatment to evaluate the usefulness of these parameters for the diagnosis of this disease. Elevated levels of one or both of these metabolites were observed in 50% of children with Stage I or II disease, in 88% of those with Stage III, in 93% of those with Stage IV and in 100% of children with Stage IV-S for a total of 88% of all patients. The clinical course of the disease can be followed readily by determination of these metabolites, successful therapy or surgery being accompanied by a corresponding decrease in the plasma levels and relapse by a corresponding increase. Determination of homovanillic and vanillylmandelic acids in plasma can obviate many of the problems associated with the collection of urine, especially in young children or ambulant patients, and thus facilitates a more frequent control with consequent advantages for the management of this disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3678274     DOI: 10.1007/bf00441600

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  11 in total

1.  The value of serial catecholamine determinations in children with neuroblastoma.

Authors:  M L VOORHESS; L I GARDNER
Journal:  Pediatrics       Date:  1962-08       Impact factor: 7.124

2.  Excretion of catecholamine catabolites by normal children.

Authors:  S E Gitlow; M Mendlowitz; E K Wilk; S Wilk; R L Wolf; L M Bertani
Journal:  J Lab Clin Med       Date:  1968-10

3.  Mass fragmentographic determination of homovanillic and 4-hydroxy-3-methoxy mandelic acids in 50 microliter plasma.

Authors:  D H Hunneman
Journal:  Clin Chim Acta       Date:  1983-12-15       Impact factor: 3.786

4.  Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors.

Authors:  E H LaBrosse; C Com-Nougué; J M Zucker; E Comoy; C Bohuon; J Lemerle; O Schweisguth
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

5.  Catecholamine-producing neural tumors other than pheochromocytoma.

Authors:  H Käser
Journal:  Pharmacol Rev       Date:  1966-03       Impact factor: 25.468

6.  A proposed staging for children with neuroblastoma. Children's cancer study group A.

Authors:  A E Evans; G J D'Angio; J Randolph
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

7.  Esthesioneuroblastoma: ultrastructural, immunohistological and biochemical investigation of one case.

Authors:  M Vollrath; M Altmannsberger; D H Hunneman; H H Goebel; M Osborn
Journal:  Arch Otorhinolaryngol       Date:  1984

8.  Effect of age on homovanillic and 4-hydroxy-3-methoxymandelic acid levels in plasma.

Authors:  D H Hunneman; W Jonas; M Gabriel; M Gahr
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

9.  Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma.

Authors:  W E Laug; S E Siegel; K N Shaw; B Landing; J Baptista; M Gutenstein
Journal:  Pediatrics       Date:  1978-07       Impact factor: 7.124

10.  Plasma dopa and catecholamines in the diagnosis and follow-up of children with neuroblastoma.

Authors:  C S Alvarado; B A Faraj; T H Kim; V M Camp; R P Bain; A H Ragab
Journal:  Am J Pediatr Hematol Oncol       Date:  1985
View more
  1 in total

1.  Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma.

Authors:  Giuliana Cangemi; Giorgio Reggiardo; Sebastiano Barco; Laura Barbagallo; Massimo Conte; Paolo D'Angelo; Maurizio Bianchi; Claudio Favre; Barbara Galleni; Giovanni Melioli; Riccardo Haupt; Alberto Garaventa; Maria V Corrias
Journal:  Onco Targets Ther       Date:  2012-11-30       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.